---
title: "Ginkgo Bioworks Reaffirmed at Buy as Strategic Refocus, Cost Cuts and New Partnerships Support Unchanged $12 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285663334.md"
description: "Analyst Brendan Smith from TD Cowen has maintained a Buy rating on Ginkgo Bioworks Holdings, keeping the price target at $12.00. His rating is based on the company's strategic refocus, cost reductions, and new partnerships, including its selection for Benchling's marketplace and AWS' Bio Discovery platform. Smith notes that these factors position Ginkgo for a scalable revenue mix and highlight disciplined cost control, which is expected to lower cash burn by FY26."
datetime: "2026-05-08T04:05:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285663334.md)
  - [en](https://longbridge.com/en/news/285663334.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285663334.md)
generator: "portal-rs"
---

# Ginkgo Bioworks Reaffirmed at Buy as Strategic Refocus, Cost Cuts and New Partnerships Support Unchanged $12 Price Target

Analyst Brendan Smith from TD Cowen maintained a Buy rating on Ginkgo Bioworks Holdings and keeping the price target at $12.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brendan Smith has given his Buy rating due to a combination of factors tied to Ginkgo Bioworks’ strategic refocus and improving efficiency. He views the completion of the biosecurity divestiture and the shift toward automation and data-generation as positioning the company for a more scalable, higher-quality revenue mix, even as near-term results reflect restructuring and program rationalization toward larger commercial customers.

He also highlights substantial operating expense reductions and reaffirmed guidance for materially lower cash burn by FY26 as evidence of disciplined cost control that extends the company’s financial runway. In addition, he sees the company’s selection for Benchling’s new marketplace, alongside AWS’ Bio Discovery platform, as opening incremental volume opportunities that can leverage Ginkgo’s automation strengths, supporting his unchanged $12 price target and Buy recommendation.

### Related Stocks

- [DNA.US](https://longbridge.com/en/quote/DNA.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md)
- [DNABW.US](https://longbridge.com/en/quote/DNABW.US.md)

## Related News & Research

- [Ginkgo Bioworks joins Waterfall Scientific-led ARPA-H consortium to build autonomous RNA drug manufacturing system](https://longbridge.com/en/news/298590935.md)
- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [BKYI: Biometric IAM platform accelerates growth amid regulatory demand and global deployments](https://longbridge.com/en/news/298369687.md)
- [CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session](https://longbridge.com/en/news/298589195.md)
- [National Franchise T.A.C.T. Celebrates Franchisee Feature in Esquire Magazine Highlighting Industry Excellence](https://longbridge.com/en/news/298459621.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**